This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): allopurinol
Description: Aloprim is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid.
Deal Structure: In June 2004, Nabi exercised its option to acquire full rights to Aloprim from DSM Pharmaceuticals. In 1999, Nabi Biopharmaceuticals acquired U.S. distribution rights to Aloprim from Catalytica Pharmaceuticals on a profit sharing basis.
In December 2006, RoundTable Healthcare Partners completed its purchase of Bioniche Life Sciences' 10% ownership stake in Bioniche Pharma, their injectable generic and specialty pharmaceuticals unit.
Nabi announced in April 2007 that it has executed a definitive agreement to sell its Aloprim for Injection product to Bioniche Teoranta. The aggregate sale proceedsfor Aloprim is $3.7 million -- Nabi will receive $1.3 million at closing, $1.4 million at the end of 2007 and $1.0 million at the end of 2008.
In July 2010, Mylan announced plans to acquire Bioniche Pharma for $550 million in cash from RoundTable Healthcare. Mylan is not assuming any of Bioniche Pharma's outstanding debt or acquiring the company's cash as part of the transaction. In...See full deal structure in Biomedtracker
Pink Sheet Nabi
Additional information available to subscribers only: